Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111385 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1201515 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1201502 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1201128 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1201460 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL4864512 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL96240 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1201657 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL1200630 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 | |
| SCHEMBL29341218 | 1.00 | THRA (0.45) | THRATHRBNR5A1MEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253634-A9 | LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | Dai Nippon Printing Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110046366-A1 | LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME | DAI NIPPON PRINTING CO., LTD. (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2253634-A1 | LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | Dai Nippon Printing Co., Ltd. (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046366-A1 | LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME | PPOX, OR10J3, ORC3 | THRA 2295/4885THRB 2750/4885NR5A1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.